Validation of the 4P's Plus screen for substance use in pregnancy validation of the 4P's Plus
- PMID: 17805340
- DOI: 10.1038/sj.jp.7211823
Validation of the 4P's Plus screen for substance use in pregnancy validation of the 4P's Plus
Abstract
Objective: The purpose of this study is to validate the 4P's Plus screen for substance use in pregnancy.
Study design: A total of 228 pregnant women enrolled in prenatal care underwent screening with the 4P's Plus and received a follow-up clinical assessment for substance use. Statistical analyses regarding reliability, sensitivity, specificity, and positive and negative predictive validity of the 4Ps Plus were conducted.
Result: The overall reliability for the five-item measure was 0.62. Seventy-four (32.5%) of the women had a positive screen. Sensitivity and specificity were very good, at 87 and 76%, respectively. Positive predictive validity was low (36%), but negative predictive validity was quite high (97%). Of the 31 women who had a positive clinical assessment, 45% were using less than 1 day per week.
Conclusion: The 4P's Plus reliably and effectively screens pregnant women for risk of substance use, including those women typically missed by other perinatal screening methodologies.
Similar articles
-
The 4P's Plus screen for substance use in pregnancy: clinical application and outcomes.J Perinatol. 2005 Jun;25(6):368-74. doi: 10.1038/sj.jp.7211266. J Perinatol. 2005. PMID: 15703775
-
Accuracy of Three Screening Tools for Prenatal Substance Use.Obstet Gynecol. 2019 May;133(5):952-961. doi: 10.1097/AOG.0000000000003230. Obstet Gynecol. 2019. PMID: 30969217 Free PMC article.
-
The challenges of screening for substance use in pregnant women: commentary on the 4P'S Plus tool.J Perinatol. 2005 Jun;25(6):365-7. doi: 10.1038/sj.jp.7211293. J Perinatol. 2005. PMID: 15915163 No abstract available.
-
Does subtle screening for substance abuse work? A review of the Substance Abuse Subtle Screening Inventory (SASSI).Addiction. 2007 Jan;102(1):41-50. doi: 10.1111/j.1360-0443.2006.01634.x. Addiction. 2007. PMID: 17207122 Review.
-
Screening psychiatric patients for illicit drug use disorders and problems.Clin Psychol Rev. 2008 Apr;28(4):578-91. doi: 10.1016/j.cpr.2007.08.002. Epub 2007 Sep 8. Clin Psychol Rev. 2008. PMID: 17900773 Review.
Cited by
-
A systematic review of validity of US survey measures for assessing substance use and substance use disorders.Syst Rev. 2024 Jun 27;13(1):166. doi: 10.1186/s13643-024-02536-x. Syst Rev. 2024. PMID: 38937847 Free PMC article. Review.
-
Association of prenatal substance exposure and the development of the amygdala, hippocampus, and parahippocampus.J Osteopath Med. 2024 Jun 26;124(11):499-508. doi: 10.1515/jom-2023-0277. eCollection 2024 Nov 1. J Osteopath Med. 2024. PMID: 38915228 Free PMC article.
-
Development and validation of the Cannabis Exposure in Pregnancy Tool (CEPT): a mixed methods study.BMC Pregnancy Childbirth. 2024 Apr 16;24(1):280. doi: 10.1186/s12884-024-06485-0. BMC Pregnancy Childbirth. 2024. PMID: 38627667 Free PMC article.
-
Child Abuse Prevention and Treatment Act, family care plans and infants with prenatal substance exposure: Theoretical framework and directions for future research.Infant Child Dev. 2022 May-Jun;31(3):e2309. doi: 10.1002/icd.2309. Epub 2022 Feb 3. Infant Child Dev. 2022. PMID: 38288357 Free PMC article.
-
The Effect of Maternal Adverse Childhood Experiences (ACEs) on Substance Use During Pregnancy.Matern Child Health J. 2023 Dec;27(Suppl 1):153-165. doi: 10.1007/s10995-023-03768-4. Epub 2023 Sep 21. Matern Child Health J. 2023. PMID: 37733152 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
